NCT07003295View on ClinicalTrials.gov

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT

BIOLOGICAL

Glofitamab

Given IV

BIOLOGICAL

Obinutuzumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT07003295 - Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy | Biotech Hunter | Biotech Hunter